Navelbine (Vinorelbine Tartrate)

Vinorelbine binds to tubulin at the vinca‑binding site, blocking microtubule assembly. This disrupts the mitotic spindle, arrests cells in the M phase of the cell cycle, and triggers apoptosis in rapidly dividing cancer cells, thereby exerting its antitumour effect.

The dose of Navelbine is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, type and stage of cancer, prior therapies, and laboratory parameters. Exact dosing regimens are not publicly disclosed and must follow the prescriber’s order.

Vinorelbine is classified as contraindicated in pregnancy and breastfeeding unless the potential therapeutic benefit justifies the risk. It may cause fetal harm, and women of child‑bearing potential should use effective contraception during treatment and for a period thereafter.

To order Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with other Vinca alkaloids such as vincristine, vinorelbine has a distinct toxicity profile, showing relatively lower neurotoxicity but higher rates of neutropenia. Its efficacy in non‑small cell lung cancer and breast cancer is comparable to other microtubule‑targeting agents, and it is often chosen for combination regimens based on tolerability and physician preference.

Navelbine must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until use, and any prepared infusion should be administered promptly according to aseptic technique.

Navelbine is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a short infusion period, following the dosing schedule prescribed by the treating oncologist. Infusion bags must be prepared under sterile conditions.

The most serious risks include severe neutropenia with fever, which can lead to life‑threatening infections, thrombocytopenia causing bleeding, and pulmonary toxicity such as interstitial pneumonitis or fibrosis. Patients should be monitored closely for signs of infection, bleeding, or respiratory distress.

Navelbine should not be used in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, in those with severe hepatic impairment, or in pregnant or nursing women unless the benefit outweighs the risk. It is also contraindicated in patients with uncontrolled infections or severe bone‑marrow suppression.